Infant Bacterial Therapeutics ABOMXSTO: IBT_B

Infant Bacterial Announces Phase III IBP-9414 Study Results

· Issued by Infant Bacterial Therapeutics AB

On 6ix: 6ix.com/news/infant-bacterial-announces-phase-iii-ibp-9414-study-results

Infant Bacterial Therapeutics AB OMXSTO:IBT_B:

  • ANNOUNCES PHASE III STUDY RESULTS PUBLISHED IN PEDIATRIC RESEARCH

  • PHASE III STUDY SHOWS 27% MORTALITY REDUCTION WITH IBP-9414

  • TREATMENT DESIGNATED AS 'BREAKTHROUGH THERAPY' AND 'RARE PAEDIATRIC DISEASE'

  • STUDY CONCLUDES IBP-9414 REDUCES MORTALITY AND NECROTIZING ENTEROCOLITIS

Infant Bacterial Therapeutics AB on 6ix

Earlier from Infant Bacterial Therapeutics

Later from Infant Bacterial Therapeutics

All Infant Bacterial Therapeutics news releases